HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bioluminescence as gold standard for validation of optical imaging modalities in peritoneal carcinomatosis animal models.

AbstractBACKGROUND:
The outcome of cytoreductive surgery in patients with peritoneal carcinomatosis is influenced by incomplete resection as a result of inadequate detection of a tumor, i.e. residual disease. The future perspective of complete resection, made possible by application of intraoperative near-infrared fluorescence imaging (NIRF), led to the development and validation of a bioluminescent colorectal peritoneal carcinomatosis xenograft rat model to act as the gold standard for the evaluation of new optical imaging modalities.
METHODS:
Twenty nude rats were inoculated intraperitoneally with 2 × 10(6) luciferase-labeled human colorectal tumor cells (HT-29-luc-D6). The peritoneal carcinomatosis index (PCI) was estimated using visual observation (PCI-VO) and VO combined with bioluminescence imaging (PCI-BLI). Subsequently, the BL images were presented, and residual tumor tissue was localized by PCI-BLI scoring and compared with the PCI-VO.
RESULTS:
BLI revealed additional tumor tissue, confirmed by HE staining, compared to VO alone in 7 out of 8 rats (p < 0.02).
CONCLUSION:
The developed model turned out to be suitable. The use of BLI for tumor detection was more sensitive compared to VO alone. In this model, BLI significantly detected residual disease, and therefore, BLI can be denominated as the gold standard for the evaluation of optical imaging modalities like NIRF.
AuthorsN J Harlaar, J W Hesselink, J S de Jong, G M van Dam
JournalEuropean surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes (Eur Surg Res) Vol. 45 Issue 3-4 Pg. 308-13 ( 2010) ISSN: 1421-9921 [Electronic] Switzerland
PMID21042026 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Validation Study)
CopyrightCopyright © 2010 S. Karger AG, Basel.
Chemical References
  • Luciferases
Topics
  • Adenocarcinoma (diagnosis, secondary, therapy)
  • Animals
  • Colorectal Neoplasms
  • Combined Modality Therapy
  • Disease Models, Animal
  • Female
  • HT29 Cells
  • Humans
  • Infrared Rays
  • Luciferases (genetics, metabolism)
  • Luminescent Measurements (methods)
  • Neoplasm, Residual (diagnosis, secondary, therapy)
  • Optical Phenomena
  • Peritoneal Neoplasms (diagnosis, secondary, therapy)
  • Prognosis
  • Rats
  • Rats, Nude
  • Transplantation, Heterologous
  • Tumor Burden

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: